Plain-English translation of NCT06283966 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new inhaler medication called budesonide, glycopyrronium, and formoterol fumarate (BGF) to see if it better protects the heart and lungs compared to an inhaler with just two of those ingredients. The study involves about 5,000 people with COPD who also have heart disease or significant heart disease risk factors. Researchers want to learn whether this medication can prevent serious heart and lung events.
People with COPD often also have heart disease, and their lungs and heart can work together in ways that make them sicker. This study exists to find out if adding an extra ingredient to the inhaler medication can better protect both the heart and lungs at the same time.
You likely qualify if…
You likely don't qualify if…
You would be randomly assigned to use one of two inhalers twice daily—either the new three-part medication or a two-part version—while the study team tracks your health. You'll visit the study site multiple times for breathing tests, heart health checks, and blood work, or participate in some visits virtually. The study continues until researchers have gathered enough information about heart and lung outcomes, which means it could last months or longer depending on your individual health events.
AI-generated summary from trial data · Aug 28, 2026 · Not medical advice
United States